Evolution of the Average Target: XP Inc.

Evolution of the Target Price: XP Inc.

Changes in Analyst Recommendations: XP Inc.

14.AXEHgWHRGRxPQkmW7NosIFzcmMTI-XDz4CCtWwekUO0.Tkhq0SC-V1EjFnvQ3rsfE2Wax5eBzRmphhebHk3UKad5A1-1DLdeWWIIJg~56a18dc14349f8f8ebed370ce1611fae
04-02 UBS Adjusts Price Target on XP to $28 From $25, Maintains Buy Rating MT
01-20 Jefferies Initiates XP at Buy With $22 Price Target MT
12-16 UBS Adjusts XP Price Target to $25 From $23, Maintains Buy Rating MT
25-10-16 UBS Adjusts Price Target on XP to $23 From $24, Maintains Buy Rating MT
25-06-23 XP Shares Drop After Downgrade From Itau BBA MT
25-06-23 Itau BBA Downgrades XP to Market Perform From Outperform, Adjusts Price Target to $21 From $20 MT
25-06-10 UBS Adjusts XP Price Target to $24 From $17, Maintains Buy Rating MT
25-06-04 Goldman Sachs Upgrades XP to Buy From Neutral, $23 Price Target MT
25-05-13 XP Shares Rise After Morgan Stanley Upgrades to Overweight From Equalweight MT
25-05-13 Morgan Stanley Upgrades XP to Overweight From Equalweight, Adjusts Price Target to $24 From $18 MT
25-04-07 UBS Adjusts Price Target on XP to $17 From $16, Keeps Buy Rating MT
25-03-18 Itau BBA Initiates XP at Outperform With $20 Price Target MT
25-01-24 XP Shares Rise After Upgrade From UBS MT
25-01-24 UBS Upgrades XP to Buy From Neutral, Cuts Price Target to $16 From $19 MT
24-12-10 BofA Securities Downgrades XP to Neutral From Buy, Price Target is $16 MT
24-11-25 UBS Cuts Price Target on XP to $19 From $21, Maintains Neutral Rating MT
24-07-11 UBS Downgrades XP to Neutral From Buy, Cuts Price Target to $21 From $30 MT
24-07-05 Bradesco BBI Downgrades XP to Neutral From Outperform, Cuts Price Target to $19 From $31 MT
24-06-05 Citigroup Adjusts Price Target on XP to $27 From $29, Maintains Buy Rating MT
24-04-30 XP Shares Decline After Goldman Sachs Downgrade MT
24-04-30 Goldman Sachs Downgrades XP to Neutral From Buy, Cuts Price Target to $23 From $30 MT
24-04-23 Morgan Stanley Downgrades XP to Equalweight From Overweight, Adjusts Price Target to $24 From $31 MT
24-03-22 Citigroup Adjusts Price Target on XP to $29 From $28, Maintains Buy Rating MT
23-12-11 UBS Adjusts XP Price Target to $30 From $31, Maintains Buy Rating MT
23-12-05 JPMorgan Upgrades XP to Overweight From Neutral, Raises Price Target to $30 From $27 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+41.15%
+29.22%
+2.84%
+54.9%
+39.3%
- - -3.38%
- - +39.85%
Average +29.13%
Weighted average by Cap. +28.09%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
85.58BRL
Average target price
121.98BRL
Spread / Average Target
+42.53%
High Price Target
135.64BRL
Spread / Highest target
+58.48%
Low Price Target
98.44BRL
Spread / Lowest Target
+15.01%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Jefferies & Co.
Itau BBA
Goldman Sachs
Morgan Stanley
BofA Securities
Citigroup
JPMorgan Chase
Credit Suisse
Bradesco
HSBC
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
85.58BRL
Average target price
121.98BRL
Spread / Average Target
+42.53%

Quarterly revenue - Rate of surprise